Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Simcere Pharmaceutical

Sanofi reception

Manufacturing issues scupper Sanofi’s sarilumab launch plans

FDA turns down the rheumatoid arthritis drug’s marketing application after routine inspection

Bristol-Myers Squibb (BMS) building

Opdivo drives gain in BMS sales, but business revamp coming

Plans to invest in biologics production with potential divestment of older brands

- PMLiVE

Merck gets early OK for Keytruda in first-line lung cancer

FDA fast-tracks approval of PD-1/PD-L1 inhibitor for treatment of NSCLC

Bristol-Myers Squibb (BMS) building

Keytruda, Opdivo narrow Tecentriq’s lead in bladder cancer

BMS’ drug is currently under FDA and EMA review in advanced urothelial carcinoma

Bristol-Myers Squibb (BMS) building

NICE U-turn on Opdivo for kidney cancer

BMS sways the watchdog with new data and a patient access scheme

Roche Basel Switzerland

Lung cancer OK for Tecentriq sets up showdown with Merck and BMS

Broad label will aid Roche’s PD-L1 inhibitor in head-to-head NSCLC market-share battle

Bristol-Myers Squibb (BMS) building

NICE turns down Opdivo but offers CDF hope

Wants more cost-effectiveness data to be gathered

Bristol-Myers Squibb (BMS) building

Opdivo data confirms poor showing in first-line NSCLC

Lung cancer drug failed to outperform both chemotherapy and Merck & Co’s Keytruda

National Institute for Health and Care Excellence NICE logo

NICE turns down Keytruda for lung cancer in draft guidance

Says long-term benefits for advanced non-small cell lung cancer treatment not proven

- PMLiVE

GSK draws line under Chinese scandal with $20m SEC settlement

Brings corruption investigation to an end with commitment to ongoing remediation reports

China flag thumb

China: Smoking prevalence greater in men while women kick habit

New study also finds the number of cigarettes smoked daily has risen

- PMLiVE

Amgen’s Kyprolis scarred by head-to-head duel with Velcade

Failed to show superior progression-free survival in first-line treatment trials

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links